Glioma News and Research

RSS

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

Minimizing neurological side effects in high-grade glioma patients may improve survival

Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

20 Apr 2011

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

A novel brain tumor vaccine clinical trial study demonstrates a longer survival time in patients with glioblastoma, according to findings being presented at the 79th Annual Scientific Meeting of the American Association of Neurological Surgeons in Denver.

12 Apr 2011

Hypericin may treat recurrent malignant brain tumors

Researchers have found that a synthetic version of hypericin, a compound naturally found in St. John's wort, may be a promising treatment for patients with recurrent malignant brain tumors. Their findings were published online on March 31, 2011 in the journal Cancer.

12 Apr 2011

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Neurosurgeons to present techniques and discuss surgical approaches at AANS meeting

Neurosurgeons from NYU Langone Medical Center will present techniques and discuss surgical approaches and applications of technology at the annual meeting of the American Association of Neurological Surgeons, held April 9-13, 2011 at the Colorado Convention Center in Denver.

11 Apr 2011

Researchers develop novel system to show how specific mutations can induce glioblastoma

Mutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults. But new research from St. Jude Children's Research Hospital scientists shows those changes alone are not sufficient to cause cancer.

15 Mar 2011

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

10 Mar 2011

New discovery in glioma-associated metabolic changes

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome", in The Proceedings of the National Academy of Sciences.

3 Mar 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

Cannabis Science extract treatments help kill cancer cells

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

23 Feb 2011

Allergies appear to reduce glioma risk

The more allergies one has, the lower the risk of developing low- and high-grade glioma, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

Rice University bioengineers and physician-scientists at Baylor College of Medicine and Texas Children's Hospital have successfully destroyed tumors of human brain cancer cells in the first animal tests of a minimally invasive treatment that zaps glioma tumors with heat. The tests involved nanoshells, light-activated nanoparticles that are designed to destroy tumors with heat and avoid the unwanted side effects of drug and radiation therapies.

2 Feb 2011

No robust conclusions possible on advantages or disadvantages of PET

Malignant gliomas are fast-growing brain tumours with poor prospects of recovery depending on disease stage. Experts hope that the examination of patients by means of positron emission tomography (PET) is more helpful in the choice of the right treatment than other procedures. In a final report the German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated the benefit of PET in the detection of recurrences. According to this report, no robust conclusions are possible on the advantages or disadvantages of PET.

20 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

Researchers describe crucial initial steps taken by measles virus attachment proteins with receptors

Mayo Clinic researchers have shown that proteins on the surface of a cell twist a viral protein into position, allowing the virus to start infection and cause disease, all in a movement as graceful as a ballroom dance. The findings appear in the current online issue of Nature Structural & Molecular Biology.

10 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

Antigenics announces name change to Agenus

Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.

6 Jan 2011

UCSF scientists explain why oligodendroglioma is more responsive to therapy than other brain tumors

For patients with glioma, the most common primary brain tumor, new findings may explain why current therapies fail to eradicate the cancer. A UCSF-led team of scientists has identified for the first time that progenitor rather than neural stem cells underly a type of glioma called oligodendroglioma.

15 Dec 2010

Glioma News and Research

Further Reading

Minimizing neurological side effects in high-grade glioma patients may improve survival

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

Hypericin may treat recurrent malignant brain tumors

Novelos Therapeutics acquires Cellectar

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

Neurosurgeons to present techniques and discuss surgical approaches at AANS meeting

Researchers develop novel system to show how specific mutations can induce glioblastoma

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

New discovery in glioma-associated metabolic changes

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Cannabis Science extract treatments help kill cancer cells

Allergies appear to reduce glioma risk

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

No robust conclusions possible on advantages or disadvantages of PET

Study supports use of telomerase inhibitors for treatment of childhood cancers

Researchers describe crucial initial steps taken by measles virus attachment proteins with receptors

Scientists identify type of cell at the origin of brain tumors

Antigenics announces name change to Agenus

UCSF scientists explain why oligodendroglioma is more responsive to therapy than other brain tumors

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News